If you can't see this message,  view it in your browser
For Students of Emory University
Monday, Nov. 29, 2021
Image-header
space
 
DRUG DISCOVERY AT EMORY
 
FDA to consider authorization of molnupiravir
An advisory committee to the U.S. Food and Drug Administration is scheduled to meet tomorrow to discuss Merck’s emergency-use authorization application for molnupiravir, an antiviral pill for COVID-19 that was discovered at Emory. Emory licensed the drug in 2020 to Ridgeback Biotherapeutics, which later partnered with Merck, to advance it through clinical trials. Molnupiravir was approved in the United Kingdom earlier this month to treat at-risk patients with mild-to-moderate COVID-19. It marks another notable chapter in Emory’s drug development efforts, which have advanced lifesaving therapies for more than three decades.

 

‘The little pill that could’ may prove useful against COVID-19
The oral antiviral molnupiravir was being developed for another purpose when Emory scientist George Painter pivoted to address the COVID-19 crisis. Painter reflects on the years of work behind getting the drug compound from there to here.

 

Video: Molnupiravir vs. COVID-19
An animated video describes how molnupiravir fools the enzymatic machine that copies the SARS-CoV-2’s RNA genome into making errors.

 

How Emory made its mark in worldwide drug discovery
Molnupiravir currently occupies center stage. However, Emory researchers can claim a string of successes, including a lifesaving drug for millions of HIV patients. Watch Emory leaders and inventors weigh in.

 

New site chronicles molnupiravir discovery and Emory drug development history
Just launched, Drug Discovery at Emory dives deep on molnupiravir and chronicles the longstanding dedication of Emory researchers to improve the lives and health of as many people as possible.
space
 
MORE ABOUT MOLNUPIRAVIR
 
United Kingdom becomes first country to approve Emory-discovered drug for COVID-19
United Kingdom becomes first country to approve Emory-discovered drug for COVID-19

Emory supports Medicines Patent Pool and Merck license agreement for molnupiravir to treat COVID-19
Emory supports Medicines Patent Pool and Merck license agreement for molnupiravir to treat COVID-19

EUA application submitted for COVID-19 antiviral discovered at Emory
EUA application submitted for COVID-19 antiviral discovered at Emory

Drug launched at Emory reduces virus that causes COVID-19 to undetectable levels
Drug launched at Emory reduces virus that causes COVID-19 to undetectable levels

View more news stories about molnupiravir and drug discovery at Emory
View more news stories about molnupiravir and drug discovery at Emory
space
 
IN THE NEWS
 
Emory-developed COVID drug seeks FDA approval

 

Emory-developed COVID drug seeks FDA approval
Nov. 25 |  George Painter and David Perryman |  Atlanta Journal-Constitution

How will the COVID pills change the pandemic?

 

How will the COVID pills change the pandemic?
Nov. 21 |  Emory University  |  The New Yorker

UK authorizes Merck antiviral pill, 1st shown to treat COVID

 

UK authorizes Merck antiviral pill, 1st shown to treat COVID
Nov. 4 |  Emory University |  Associated Press

How antiviral pill molnupiravir shot ahead in the COVID drug hunt

 

How antiviral pill molnupiravir shot ahead in the COVID drug hunt
Oct. 8 |  George Painter |  Nature
space
 
Emory University

 

 
Useful Links
Emory Forward
Campus Life
Academic Calendars
Emory Libraries

 

 
Dooley Report
About Us
Past Issues
Subscribe
Contact Us
Emory Home  |  Forward to a Friend
FacebookTwitterInstagramLinkedinRSS
Editor: Leigh DeLozier
Executive Director of Communications and Editor in Chief: Laura Douglas-Brown
Interim Vice President of Communications and Marketing: Cameron Taylor

Dooley Report is published by  Communications and Public Affairs
Read the Dooley Report Guidelines
Copyright 2021 Emory University | All Rights Reserved
201 Dowman Drive, Atlanta, Georgia 30322 USA | 404.727.6123